TOP TEN perturbations for 38861_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38861_at
Selected probe(set): 206345_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38861_at (206345_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
hepatocyte (ESC) / HepaRG
Relative Expression (log2-ratio):-9.088594Number of Samples:8 / 12
Experimental | hepatocyte (ESC) |
Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
Control | HepaRG |
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
Hep-G2 / HepaRG
Relative Expression (log2-ratio):-8.868397Number of Samples:9 / 12
Experimental | Hep-G2 |
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: | |
Control | HepaRG |
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
hepatoblastoma study 1 (mixed epithelial and mesenchymal) / normal liver tissue
Relative Expression (log2-ratio):-5.5664883Number of Samples:4 / 5
Experimental | hepatoblastoma study 1 (mixed epithelial and mesenchymal) |
Liver tumor tissue samples from children with hepatoblastoma (mesenchymal type (MEM-HB); mixed epithelial and mesenchymal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
Control | normal liver tissue |
Normal liver tissue samples. |
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG) / vehicle (DMSO) treated HepaRG cell sample
Relative Expression (log2-ratio):-5.298958Number of Samples:3 / 12
Experimental | 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG) |
HepaRG cells exposed to 7500 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Chemical was added at day 19 of cultivation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:--- | |
Control | vehicle (DMSO) treated HepaRG cell sample |
HepaRG cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Firstly, cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Then the vehicle was added. |
hepatoblastoma study 1 (epithelial mixed) / normal liver tissue
Relative Expression (log2-ratio):-5.162652Number of Samples:12 / 5
Experimental | hepatoblastoma study 1 (epithelial mixed) |
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); epithelial mixed subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
Control | normal liver tissue |
Normal liver tissue samples. |
hepatoblastoma study 1 (NOS) / normal liver tissue
Relative Expression (log2-ratio):-5.113366Number of Samples:5 / 5
Experimental | hepatoblastoma study 1 (NOS) |
Liver tumor tissue samples from children with hepatoblastoma (NOS). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
Control | normal liver tissue |
Normal liver tissue samples. |
HCC study 18 (very advanced) / normal liver tissue
Relative Expression (log2-ratio):-4.8058367Number of Samples:3 / 10
Experimental | HCC study 18 (very advanced) |
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded. | |
Control | normal liver tissue |
Normal liver tissue samples obtained from the healthy livers of patients undergoing resection for hepatic hemangioma, focal nodular hyperplasia, adenoma/cystadenoma, neuroendocrine tumor, and living donor liver transplantation. |
HCC study 18 (very advanced) / dysplastic liver nodule study 1
Relative Expression (log2-ratio):-4.687091Number of Samples:3 / 17
Experimental | HCC study 18 (very advanced) |
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded. | |
Control | dysplastic liver nodule study 1 |
Dysplastic nodule tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded. |
hepatoblastoma study 1 (embryonal) / normal liver tissue
Relative Expression (log2-ratio):-4.5478306Number of Samples:7 / 5
Experimental | hepatoblastoma study 1 (embryonal) |
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); embryonal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
Control | normal liver tissue |
Normal liver tissue samples. |
HCC study 18 (very advanced) / hepatitis C study 10
Relative Expression (log2-ratio):-4.3371286Number of Samples:3 / 13
Experimental | HCC study 18 (very advanced) |
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded. | |
Control | hepatitis C study 10 |
Cirrhotic tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Ten out of 13 samples were obtained from patients with hepatocellular carcinoma. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded. |